When Treating mAPMN/S PC (mHSPC), AIM for PLUVICTO Even Earlier, in Combination With ARPI

Identifying patients for PLUVICTO is more important than ever. Key criteria for PLUVICTO include a diagnosis of prostate-specific membrane antigen positive (PSMA+) metastatic hormone-sensitive prostate cancer (mHSPC).¹

Identifying Patients

With approval in an earlier setting, how do you see your practice changing?

AIM for a better treatment in mHSPC by adding a PSMA-targeted therapy to ARPI¹

AIM: After diagnosis, in combination with ARPI, Imaging confirms targetable PSMA+ disease, Metastatic HSPC

ARPI, androgen receptor pathway inhibitor; HSPC, hormone-sensitive prostate cancer; mAPMN/S PC, metastatic androgen pathway modulation-naive or -sensitive prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PSMA, prostate-specific membrane antigen.

Patient Profiles

More patients eligible for PLUVICTO in the metastatic setting

Plan for PLUVICTO in mHSPC: Start PLUVICTO with ARPI after diagnosis¹

Jeffrey (high volume), 66

Diagnosed with high-volume mHSPC

PSMA+ disease
6 bone metastases (2 lesions beyond the veterbral bodies and pelvis) and 3 lymph node metastases
ECOG 1
Gleason 9
PSA: 51 ng/mL
Mild-to-moderate, disease-related symptoms

Wants to continue his Saturday shuffleboard games with his recreational league

Grant (low volume), 68

Diagnosed with low-volume, de novo mHSPC

PSMA+ disease
3 bone metastases and 4 lymph node metastases
ECOG 0
Gleason 8
PSA: 19 ng/mL
No prior prostate cancer treatment
Mild disease-related symptoms

Wants to continue teaching his grandson guitar on the weekends

Hypothetical patient cases.

ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen.

Plan for PLUVICTO

Get Your Patients on PLUVICTO Promptly After mHSPC Diagnosis

3 ways to accelerate the PLUVICTO referral process

Proactively identify PLUVICTO Treatment Centers

*There are over 833 PLUVICTO treatment sites in the US. Please note that the PLUVICTO Treatment Centers listed are only those that have authorized their participation on the PLUVICTO website.³
^†Primary plans only; an additional 1-2 days if secondary plan coverage review is required.

Find a treatment center Learn more about Novartis Patient Support

CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography.

Identifying Patients With Metastatic APMN/S Prostate Cancer (mHSPC) for PLUVICTO in Your Urology Practice

Urologist Neal Shore, MD, discusses identifying patients with PSMA‑positive mAPMN/S prostate cancer (mHSPC) who may be appropriate for PLUVICTO, including early identification and multidisciplinary coordination in practice.

Which of your patients with PSMA+ mHSPC could benefit from PLUVICTO + ARPI now?

See the data in mHSPC

< Previous: Overview of mHSPC

Next: mHSPC Efficacy >